Darleukin/fibromun - Philogen

Drug Profile

Darleukin/fibromun - Philogen

Alternative Names: Daromun; L19-IL2 + L19-TNF; L19IL2-L19TNF; L19IL2/L19TNF

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor agonists; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma

Most Recent Events

  • 25 Jun 2018 Philogen plans the Neo-DREAM phase III trial for Melanoma in June 2018 , (NCT03567889)
  • 26 Feb 2018 Phase-III clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Neoadjuvant therapy) in USA (Intralesional) (Philogen pipeline, February 2018)
  • 12 Oct 2017 The US FDA approves IND application for darleukin/fibromun in Malignant melanoma (Metastatic disease, Neoadjuvant therapy, Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top